Learn more about the exciting field of intratumoral immunotherapy and OncoSec’s role as a key leader in this emerging space.
Watch the Video
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform
32nd Society for Immunotherapy of Cancer Annual Meeting | November 8-12, 2017
National Harbor, MD
Our core technology platform continues to advance through clinical trials for various cancers.
The ImmunoPulse® platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.
PDF | 2.0 MB
PDF | 1.0 MB